CAR-T 治疗期间患者报告结局和活动数据的纵向收集：可行性、可接受性和数据可视化

Background: Clinicians must closely monitor patients for toxicities after chimeric antigen receptor T-cell therapy (CAR-T). Patient-reported outcomes (PROs) (e. g. , toxicities, quality of life) and activity data (e. g. , steps, sleep) may complement clinicians observations.

This study tested the feasibility and acceptability of collecting PROs and activity data from patients with hematologic malignancies during CAR-T and explored preliminary data patterns. Methods: Participants wore a Fitbit tracker and completed PROs at several timepoints through 90-days post-infusion. Feasibility was assessed with a priori benchmarks for recruitment ( 50%), retention ( 70%), PRO completion ( 70%), and days wearing the Fitbit ( 50%). Acceptability was assessed with participant satisfaction (a priori benchmark > 2 on a 0 4 scale). Results: Participants (N = 12) were M = 66 years old (SD = 7).

Rates of recruitment (68%), retention (83%), PRO completion (85%), and days wearing the Fitbit (85%) indicated feasibility. Satisfaction with completing the PROs (M = 3. 2, SD = 0. 5) and wearing the Fitbit (M = 2. 9, SD = 0. 5) indicated acceptability. Preliminary data patterns suggested that participants with better treatment response (vs.

progressive disease) had a higher toxicity burden. Conclusions: Longitudinal PRO and activity data collection was feasible and acceptable. Data collected on a larger scale may be used to specify risk prediction models to identify predictors of severe CAR-T-related toxicities and inform early interventions.